Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies (Nasdaq: TSHA), a clinical-stage biotech company developing AAV-based gene therapies for CNS diseases, has granted a stock option to a new employee.

Rhea-AI Summary

Taysha Gene Therapies (Nasdaq: TSHA), a clinical-stage biotech company developing AAV-based gene therapies for CNS diseases, has granted a stock option to a new employee. The inducement grant includes options to purchase 90,000 shares at an exercise price of $2.63 per share under the company's 2023 Inducement Plan.

The stock option has a 10-year term with a four-year vesting schedule: 25% vesting after one year and the remaining 75% vesting monthly over the following 36 months, subject to continued employment.

Argus Aug 4 session

+3.04% close to close Open Argus

Details

News Market Reaction – TSHA

On Aug 4, the first trading day after this news, TSHA closed 3.04% above the previous close.

Data tracked by StockTitan Argus for the Aug 4 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DALLAS, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on August 1, 2025, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 90,000 shares of the Company's common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option has an exercise price of $2.63 which is equal to the closing price of Taysha's common stock on the date of grant. The stock option has a 10-year term and will vest over four years, with 25% of the option vesting on the first anniversary of the vesting commencement date and the remaining 75% of the option vesting in equal monthly installments over the 36 months thereafter. Vesting of the stock option is subject to such employee's continued service to Taysha on each vesting date.

About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.

Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com

Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options did Taysha Gene Therapies (TSHA) grant to its new employee?

Taysha granted options to purchase 90,000 shares at an exercise price of $2.63 per share, with a 10-year term and four-year vesting schedule.

What is the vesting schedule for TSHA's new employee stock options?

The options vest over 4 years, with 25% vesting after the first year and the remaining 75% vesting in equal monthly installments over 36 months.

What is Taysha Gene Therapies' (TSHA) main business focus?

Taysha is a clinical-stage biotechnology company developing AAV-based gene therapies for severe monogenic diseases of the central nervous system (CNS).

Under which plan were the TSHA stock options granted?

The options were granted under the Taysha Gene Therapies 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).